论文部分内容阅读
目的：探讨两阶段房水引流物植入手术在新生血管性青光眼治疗中的应用价值。方法：对１３例新生血管性青光眼患者行两阶段房水引流物植入手术，并根据不同的病因及眼压控制情况采取相应的改良技术和辅助治疗，病人追踪随访时间为６～１２个月。结果：所有病例术前眼压大于等于２３ｍｍＨｇ（３．０５ｋＰａ），手术治疗后最后一次复查结果显示眼压控制在６～２１ｍｍＨｇ（０．７９８～２．７９３ｋＰａ）之间７例（约占５４％），加用降眼压药后眼压控制在２１ｍｍＨｇ（２．７９３ｋＰａ）２例，总成功率近７０％。８例视力保持在术前水平或有所提高（占６２．３％），５例由于原发病恶化及眼压控制不良，视力较术前下降（占３７．６％）。结论：两阶段房水引流物植入手术为新生血管性青光眼的治疗提供了新的选择
Objective: To investigate the value of two-stage aqueous humor implantation in the treatment of neovascular glaucoma. Methods: Thirteen patients with neovascular glaucoma underwent two-stage aqueous humor implantation. According to different etiologies and intraocular pressure (IOP) control, appropriate improvements and adjuvant therapy were performed. The follow-up time ranged from 6 to 12 months . Results: The preoperative intraocular pressure (IOP) was higher than or equal to 23mmHg (3.05kPa) in all cases. The last recheck after operation showed that intraocular pressure was controlled in 7 cases (6% ~ 21mmHg, 0.798 ~ 2.793kPa) ), Plus intraocular pressure after ocular hypotensive control in 21mmHg (2.793kPa) in 2 cases, the total success rate of nearly 70%. 8 cases of visual acuity maintained at the preoperative level or increased (62.3%), 5 cases of primary disease due to deterioration and poor control of intraocular pressure, visual acuity decreased compared with preoperative (37.6%). Conclusion: The two-stage aqueous humor implantation provides a new option for the treatment of neovascular glaucoma